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ABSTRACT: Tailored ruthenium(IV) complexes can
catalyze the isomerization of allylic alcohols into saturated
carbonyl derivatives under physiologically relevant con-
ditions, and even inside living mammalian cells. The
reaction, which involves ruthenium-hydride intermediates,
is bioorthogonal and biocompatible, and can be used for
the “in cellulo” generation of fluorescent and bioactive
probes. Overall, our research reveals a novel metal-based
tool for cellular intervention, and comes to further
demonstrate the compatibility of organometallic mecha-
nisms with the complex environment of cells.
Enzymes catalyze a myriad of chemical transformations thatare essential to life, including hydrolysis, ligations,
isomerizations or redox processes.1 Chemists are not con-
strained to generate life-sustaining reactions, and along the
years have invented many catalytic processes that do not occur
in nature. Especially appealing are those transformations
involving metal catalysis.2 While these reactions are less
efficient than those promoted by enzymes, they present a
broader scope, and are more versatile and mechanistically
diverse. Therefore, exporting the power of “non-natural” metal
catalysis to the biological arena might open unforeseen
opportunities for metabolic or genetic intervention, and unveil
new tools in therapy and diagnosis.
Unfortunately, most transition metal-catalyzed processes
occur under conditions that are not compatible with aqueous
and biological settings, and therefore, performing these
reactions under physiological environments is certainly
challenging. Nonetheless, along recent years several groups
have demonstrated the viability of promoting bioorthogonal
metal-mediated reactions in biological buffers, and even in
living settings.3 While the area is yet in its infancy, there have
been reports on biocompatible metal-promoted deprotections
(Pd, Ru),4 click-like annulations (Cu or Ru),5 cross-couplings
(Pd),6,4b,i and even gold-promoted carbocyclizations.7
Sadler and Do have independently reported the use of
osmium or iridium complexes to alter NADH/NAD+ cellular
equilibriums, or promote reductions of specific aldehydes or
ketones (Figure 1a).8 Albeit the efficiency of these processes
was low, these studies suggest that metal-hydride species can
be generated inside cells. In light of these observations, and
considering previous contributions by Gimeno and co-workers
on a ruthenium-mediated isomerization of allylic alcohols to
ketones in water,9 we questioned whether this type of redox-
neutral processes, which likely involve ruthenium hydride
species, could be achieved in biorelevant media or even in
intracellular settings. Do the ruthenium intermediates survive
to the stringent conditions of a complex biological buffer or a
living cell? Are the hydride intermediates compatible with
biological components? Can this “non-natural” metal catalysis
promote biological responses?
Herein we provide some answers to these questions, by
reporting the first metal-catalyzed isomerization reaction that
can be carried out under biological conditions, and more
importantly, in the interior of living mammalian cells (Figure
1b). The reaction is promoted by a ruthenium(IV) catalyst
that combines water solubility with some lipophilicity. The
redox-neutral isomerization allows to transform nonfunctional,
abiotic allyl alcohols into fluorescent or bioactive ketones, in
the interior of living mammalian cells.
The viability of the isomerization was first explored using 1-
phenylprop-2-en-1-ol (1a) as substrate, and the bis-allyl
Ru(IV) complex [Ru] as catalyst (Table 1 and S1).10 The
reaction is very efficient in water and PBS at physiological
temperatures (37 °C), even using only 1 mol % of the metal
complex (92%, 1.5 h). More importantly, the transformation
can be efficiently accomplished in complex cell culture media,
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Figure 1. (a) Transfer hydrogenations have been developed to either
alter the redox status of cells or to reduce abiotic substrates; (b) this
work, and ruthenium-hydride intermediates that are likely involved in
the reaction.
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such as DMEM (Dubelcco’s modified Eagle’s medium), and
even in cell lysates (using 5 mol % of catalyst).
The efficiency and orthogonality of the reaction can be
replicated with other substrates containing modified aryl or
naphthyl substituents to give the expected ketones (Table 1,
2a−d and 2f−g, respectively), as well as with aliphatic
derivatives (Table 1, product 2e). Other ruthenium catalysts
like [RuCp*Cl(COD)], [RuCp(MeCN)3][PF6] or [RuCl2(p-
cymene)]2 do work in water, but perform very poorly in cell
lysates. We also tested the iridium complex employed by Do
and co-workers for the reduction of carbonyl compounds, as
well as [IrCl2Cp*]2,
11 but isomerization yields were very low
(Table S1). Therefore, complex [Ru] seems to present the best
balance between reactivity and stability, when used in
biologically relevant media.
While the mechanism of the reaction has not been fully
elucidated,12,9a,b it likely involves an initial aquation of the
precatalyst, followed by coordination of the allylic alcohol to
the ruthenium center and β-hydrogen elimination to generate
hydride intermediate of type I (Figure 1b). An intramolecular
hydride transfer produces an oxo complex (type II) that
releases the product and regenerates the Ru(IV) catalyst.
The presence of ruthenium hydride intermediates was
confirmed by deuteration experiments (Section S5), which
demonstrated that they survive under stringent conditions of a
milieu like DMEM. The high catalytic activity and orthogon-
ality of the ruthenium complex [Ru] under biologically
relevant conditions, prompted us to evaluate the viability of
performing the reaction in native cellular settings. This
required a way of monitoring the process, and therefore we
designed the substrate 1g, which displays very low fluorescence
above 500 nm when excited at 385 nm. However, the isomeric
ketone product 2g is highly emissive at the same wavelength of
excitation (Figures S1−S3).
The intracellular reactions were explored in human (A549
and HeLa), and animal (Vero) cell lines. Confocal microscopy
of live cells treated as indicated in the caption of Figure 2c,
revealed that there is a considerable intracellular buildup of
green fluorescence after 1 h, mainly located in the cytosol, even
using only 10 μM of [Ru] and 100 μM of substrate (Figure 2b,
panel B). Considering the mean value of corrected total cell
fluorescence (CTCF) there is an increase of up to 38-fold in
the emission of cells treated with 1g, when they had been
previously preincubated with the ruthenium complex (Figure
2c). Control experiments of untreated cells confirmed that
such increase is a consequence of the intracellular formation of
the product. Similar results were obtained with A549 and Vero
cells (Figures S6 and S7).
The formation of the expected product 2g was further
confirmed by LC-MS analysis of methanolic extracts of the
cells after running the reaction for 6 h, and 2-fold washing with
DMEM and PBS. The amount of product in the washings was
low; however, the methanolic extracts contained a significant
amount of ketone 2g.13 Importantly, using LC-MS techniques,
and appropriate calibration curves, we could also quantify the
product generated inside cells (Figure 3a and Figure S11). The
formation of the product 2g increases with time, which
demonstrates the persistence of a reactive metal complex inside
the cells. ICP-MS analysis of cellular extracts obtained after
Table 1. Scope of the Ruthenium Catalyzed Isomerization
of Allylic Alcoholsa
aPerformed using 1 (0.2 mmol), milieu (1.0 mL) and [Ru] (2 mol
%). b[Ru] (5 mol %). c[Ru] (5 mol %), cells lysates 7 mg/mL.
dMilieu with 20% THF.
Figure 2. Reactivity of ruthenium complex in living cells. (a)
Ruthenium catalyzed isomerization of allylic alcohol 1g; (b)
Fluorescence micrographies of HeLa cells (confocal): (A) cells
incubated with substrate 1g (brightfield and green channel); (B) cells
incubated with [Ru], washed and treated with substrate 1g
(brightfield and green channel); (C) cells incubated with product
2g (brightfield and green channel); (c) CTFC measurements in
HeLa, Vero and A549 cells. Reaction conditions: cells were incubated
with [Ru] (10 μM) for 30 min, followed by two washings with
DMEM and treatment with substrate 1g (100 μM) for 1 h. Error bars
represent the standard error of three independent experiments. λex =
385 nm, λem = 520−700 nm. Scale bar: 12.5 μm.
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exposing HeLa cells to 10 or 25 μM of [Ru], and thoroughly
washed with DMEM, revealed a ruthenium content of 3.5 or
11.1 ng/106 cells, respectively (Figure 3b), while untreated
cells contain over 0.2 ng/106 cells (Figure S10). Combining
this information with the amount of intracellular product, it is
possible to calculate turnover numbers (TON) with a relatively
good accuracy (Figure 3b). Indeed, we found a turnover of
over 22 in experiments with cells treated with 10 μM of [Ru]
and 100 μM of substrate, after 6 h (Section S12). To our
knowledge this represents the first quantitative demonstration
of turnover in an organometallic intracellular reaction.
While the above data demonstrate the viability of achieving
ruthenium-mediated isomerizations in native intracellular
settings, an important challenge in this nascent scientific field
of cellular metallocatalysis consists of the intracellular
generation of active products.14 Up to now, these studies
have been essentially restricted to uncaging reactions from
appropriately protected precursors. We therefore wondered
whether the isomerization reaction could also be associated
with changes in some biological activity. Using standard MTT
techniques, we confirmed that using concentrations up to 100
μM, neither the ruthenium complex nor the substrate 1g or
product 2g presented noticeable toxicities after 6 h (Figure
3c). However, after 24 h, we observed toxicity in the case of
the product (32% of cell death, Figure S4). In order to study
the effect of the “in cellulo” generation of the product 2g, we
added 100 μM of the substrate 1g to cells that had been
treated with 50 μM of [Ru], and thoroughly washed with
DMEM. In this case, we observed a higher decrease in viability
(Figure 3c, 45% of death after 24 h). This response is also
noticeable even after only 6 h, when more than 30% of the cells
died, 30 times more than that observed with the substrate
(Figure 3c). Given than the complex [Ru] is not toxic at such
concentration (Figure S5), these results suggest that the
intracellular generation of the product produces a more
effective biological response than its external addition.
Finally, considering the well-known Michael type of
reactivity of α,β-unsaturated systems, especially for thiol
nucleophiles, we envisioned the use of our ruthenium-
mediated isomerization to generate glutathione (GSH)
depleting agents. We first confirmed that the ruthenium
catalyst can efficiently convert diallyl alcohols of type 3 into the
corresponding α,β-unsaturated ketones 4, even in cell lysates
(Figure 4a). In a preliminary screening with HeLa cells, we
could observe that some of these ketones, like 4b, promoted
around 20% consumption of GSH. We therefore carried out a
standard isomerization experiment in living cells using 50 μM
of [Ru] and 100 μM of 3b. Analysis of the level of GSH after 6
h confirmed a substantial decrease of the intracellular GSH
concentration (over 40% consumption of GSH, average of
three experiments, Figure 4b). Given that the catalyst and the
substrate do not alter the levels of GSH, the observed changes
must arise from the in situ generation of the product. While
these biological results should be viewed as a preliminary proof
of concept, they demonstrate that the potential of metal
catalysis to generate bioactive products inside cells is not
limited to standard uncaging reactions.
Figure 3. (a) Extracted ion chromatogram of the product 2g
generated intracellularly (methanolic extract). HeLa cells pretreated
with 10 μM of [Ru] for 50 min were washed twice and incubated with
100 μM of substrate 1g for 30 min/6 h; (b) turnover numbers of
intracellular catalysis at 10 and 25 μM of catalyst loading (the
quantification was performed considering the total crude material
after methanolic extract and two washing steps (DMEM and PBS));
(inset) ICP-MS values of the intracellular accumulation of ruthenium
after incubation of cells in DMEM with 10 or 25 μM (in DMSO) for
50 min, double washing with PBS and digestion with HNO3; (c)
cytotoxicity studies in HeLa cells. Reaction conditions: cells were
incubated with either substrate 1g (100 μM) or product 2g (100 μM)
for 6/24 h. Alternatively, cells were mixed with [Ru] (50 μM) for 30
min, washed twice with DMEM and treated with substrate 1g (100
μM) for 6/24 h (labeled as intracellular reaction). Right bar: cells
were incubated with [Ru] (50 μM) for 30 min, followed by two
washings with DMEM and the toxicity checked after 24 h. Error bars
represent the standard error of three independent experiments.
Figure 4. Generation of α,β-unsaturated ketones. (a) Scope of the
ruthenium-catalyzed isomerization. aPerformed using 3 (0.2 mmol),
solvent (1.0 mL) and [Ru] (2 mol %). b[Ru] (5 mol %), cells lysates
7 mg/mL. (b) Selected biological studies of GSH consumption using
the transformation 3b→4b as a model. Reaction conditions: for
intracellular catalysis, cells were incubated with [Ru] (50 μM) for 30
min, followed by two washings with DMEM and treatment with
substrate 3b (100 μM), for 6 h. For control experiments, cells were
incubated with substrate 3b or product 4b (100 μM) for 6 h. Error
bars represent the standard error of three independent experiments.
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In summary, we have developed the first metal-catalyzed
isomerization reaction that can be achieved inside living cells.
The reaction, promoted by a Ru(IV) complex, involves an
intramolecular hydride-transfer process and takes place with a
remarkable intracellular turnover. Our results demonstrate that
typical intermediates of catalytic organometallic reactions,
including ruthenium-hydride complexes, can survive the
crowded atmosphere of cell lysates or even living cells.
Importantly, the substrates can be engineered for the “in
cellulo” generation of fluorescent products or bioactive
molecules. Overall, these results open new avenues in this
emerging research field at the boundary of metal catalysis and
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